Good Numbers, Declining Function: What Your A1C Isn't Telling You About Pancreatic Health

For most people living with type 2 diabetes, the A1C test serves as the primary report card for how well their treatment plan is working. When that number drops from 8.2% to 6.9%, it feels like progress — and clinically speaking, it is. Lower A1C values are associated with reduced risk of neuropathy, retinopathy, and kidney disease. But a troubling paradox sits beneath the surface of those improved readings: the very disease driving diabetes forward does not necessarily slow down just because blood sugar levels improve.

This is not a reason to abandon medication or lose confidence in your treatment plan. It is, however, a reason to ask more informed questions at your next appointment — particularly if sitagliptin or another DPP-4 inhibitor is part of your regimen.

Understanding the Two-Track Nature of Type 2 Diabetes

Type 2 diabetes is fundamentally a disease of two interrelated failures. The first is insulin resistance — the body's cells become less responsive to insulin signals, forcing the pancreas to compensate by producing more. The second, and arguably more consequential over the long term, is progressive beta cell dysfunction. The beta cells housed in the pancreatic islets of Langerhans are responsible for sensing blood glucose and secreting insulin in response. In type 2 diabetes, these cells are under constant physiological stress, and their functional capacity tends to erode over years and decades.

Here is where the paradox emerges: a medication can successfully lower blood glucose by enhancing the efficiency of the insulin that remains, or by reducing the liver's glucose output — all without halting, or even meaningfully slowing, the underlying beta cell deterioration. The meter improves. The machinery continues to wear down.

How Sitagliptin Works — And Where Its Influence Ends

Sitagliptin belongs to the class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. Its mechanism centers on preserving the activity of incretin hormones — primarily GLP-1 and GIP — which are released from the gut after meals. Under normal circumstances, these hormones are rapidly broken down by the DPP-4 enzyme. Sitagliptin blocks that enzyme, allowing incretins to remain active longer and stimulate the pancreas to release insulin in a glucose-dependent manner.

This mechanism is genuinely elegant. Because insulin secretion only increases when blood glucose is elevated, the risk of hypoglycemia is low. The drug also suppresses glucagon, a hormone that would otherwise signal the liver to release additional glucose into the bloodstream.

What sitagliptin does not do — at least not in a clinically definitive way — is regenerate beta cells or permanently reverse their functional decline. Early preclinical studies in animal models raised cautious optimism that DPP-4 inhibition might support beta cell survival or even stimulate modest regeneration. Translating those findings into confirmed human outcomes has proven considerably more difficult.

What the Clinical Research Actually Shows

The TECOS trial, one of the largest cardiovascular outcomes studies involving sitagliptin, confirmed the drug's safety profile across a broad population of patients with type 2 diabetes and established cardiovascular disease. It did not, however, demonstrate long-term preservation of beta cell mass or function beyond what would be expected from any agent that reduces glucotoxicity — the cellular damage caused by chronically elevated blood sugar.

Separate mechanistic studies measuring C-peptide levels and beta cell secretory capacity over multi-year follow-up periods have produced mixed results. Some research suggests that earlier initiation of DPP-4 inhibitor therapy, before beta cell reserves are severely depleted, may be associated with slower functional decline compared to later-stage intervention. This finding, while preliminary, carries a meaningful clinical implication: the timing of treatment may matter as much as the treatment itself.

The ADOPT trial, which compared early glucose-lowering agents over several years, reinforced the broader principle that type 2 diabetes is a progressive condition regardless of which medication is used. Most patients eventually require additional therapy or dose adjustments — not because their medication has failed in a conventional sense, but because the disease itself has advanced.

Why A1C Alone Is an Incomplete Picture

A1C measures the average blood glucose level over approximately three months by assessing how much glucose has attached to hemoglobin in red blood cells. It is a reliable and widely validated marker. But it measures an outcome — average blood sugar — rather than the underlying biological capacity that produces that outcome.

Two patients can have identical A1C readings of 7.0% while existing in very different physiological states. One may be achieving that number with modest medication and reasonable beta cell reserve. The other may be on multiple agents at higher doses, with significantly compromised beta cell function, barely maintaining the same number. The A1C looks the same. The trajectory of their disease does not.

Clinicians increasingly recognize the value of complementary markers. Fasting C-peptide levels, which reflect the amount of insulin the pancreas is producing, can provide a window into beta cell reserve that A1C simply cannot. HOMA-B (Homeostatic Model Assessment of Beta Cell Function) is another research-grade tool used in clinical studies to estimate beta cell capacity over time. While these tests are not yet routine in most primary care settings, they represent the kind of deeper assessment that a more complete picture of diabetes health would require.

Having a More Informed Conversation With Your Provider

None of this is meant to suggest that sitagliptin is an inadequate treatment or that patients should be alarmed by the concept of disease progression. Effective glycemic control genuinely matters. Reducing A1C does lower the risk of serious complications, and sitagliptin has a well-documented safety profile that makes it a reasonable choice for many patients — particularly those at risk for hypoglycemia or those with cardiovascular considerations.

The goal is not to replace one metric with another, but to expand the conversation. Patients who understand that their medication is managing symptoms of an ongoing disease — rather than curing or permanently arresting it — are better positioned to engage proactively with their care team. Questions worth raising include how frequently beta cell function is being assessed, whether current therapy is adequate as the disease progresses, and at what point combination therapy or a different drug class might be worth considering.

Lifestyle factors also remain relevant to this equation. There is consistent evidence that sustained weight loss, regular physical activity, and dietary modification can reduce the metabolic burden on beta cells. These interventions do not simply complement medication — they may, in some cases, slow the rate of functional decline in ways that medication alone cannot fully replicate.

The Takeaway: Manage the Numbers, Understand the Disease

A well-controlled A1C is worth celebrating. It reflects discipline, adherence, and the effective action of your medication. But it is a snapshot, not a full portrait. Type 2 diabetes is a condition that evolves, and the most effective long-term management comes from understanding both what your treatment is doing and what it is not doing.

Sitagliptin can be a valuable tool in that management — one that works best when patients and providers alike recognize it as part of a broader, ongoing strategy rather than a definitive solution. The numbers on your lab report tell an important part of the story. Making sure you understand the full chapter is equally important.